NCT00100282View on ClinicalTrials.gov

Safety Study of PPI-1019 in Patients With Mild-Moderate Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

May 31, 2003

Study Completion Date

June 30, 2005

Conditions
Alzheimer's Disease
Interventions
DRUG

PPI-1019 (APAN)

Trial Locations (2)

92868

Department of Psychiatry & Human Behavior at the University California, Irvine, Orange

08540

Global Medical Institutes LLC, Princeton

Sponsors
All Listed Sponsors
lead

PRAECIS Pharmaceuticals Inc.

INDUSTRY